• Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at approximately $480 million
• For the remaining three years beginning in 2023, Emergent will provide a flexible capacity deployment model to support annual dose requirements

GAITHERSBURG, Md., July 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac^® technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.

• Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing facility to increase campus footprint and build out advanced therapy capability
• Advanced therapy CDMO drug substance manufacturing services expected to be available beginning in 2023
• Expansion will enable molecule-to-market CDMO services in viral vector and gene therapy utilizing Emergent’s integrated network with development services and drug product manufacturing to be offered out of its Gaithersburg and Rockville, Maryland facilities, respectively   

GAITHERSBURG, Md., June 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it will further strengthen its contract development and manufacturing (CDMO) capabilities by expanding into viral vector and gene therapy. The company will invest $75 million in its Canton, Massachusetts facility, which is focused on the development and manufacturing of drug substance for live viral vaccines, including the company’s smallpox vaccine.